Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
PYXS Pyxis Oncology
- 1.320
- +0.020+1.54%
Close Feb 14 16:00 ET
- 1.319
- -0.001-0.09%
Post 19:59 ET
78.49MMarket Cap-1.25P/E (TTM)
1.350High1.265Low821.65KVolume1.310Open1.300Pre Close1.08MTurnover2.29%Turnover RatioLossP/E (Static)59.47MShares6.85052wk High0.51P/B47.46MFloat Cap1.23052wk Low--Dividend TTM35.95MShs Float19.000Historical High--Div YieldTTM6.54%Amplitude1.100Historical Low1.312Avg Price1Lot Size
About Pyxis Oncology Company
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Company Profile
SymbolPYXS
Company NamePyxis Oncology
Listing DateOct 8, 2021
Issue Price16.00
Founded2018
CEODr. Lara S. Sullivan, M.D.
MarketNASDAQ
Employees50
Fiscal Year Ends12-31
Address321 Harrison Avenue
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02118
Phone1-617-221-9059
Websitehttp://www.pyxisoncology.com
Company Executives
- Name
- Position
- Salary
- Dr. Lara S. Sullivan, M.D.
- Chief Executive Officer, President and Director
- 4.44M
- Pamela Yanchik Connealy, M.B.A.
- Chief Financial Officer and Chief Operating Officer
- 1.82M
- Jitendra Wadhane
- Chief Accounting Officer
- --
- Ken Kobayashi, F.A.C.P.,M.D.
- Chief Medical Officer
- 880.01K
- John L. Flavin
- Chairman of the Board
- 395.48K
- Darren S. Cline, M.B.A.
- Independent Director
- 357.48K
- Dr. Jakob Dupont, M.D.
- Independent Director
- 538.27K
- Dr. Freda C. Lewis-Hall,M.D.
- Independent Director
- 341.98K
- Dr. Rachel Humphrey, M.D.
- Independent Director
- 287.71K
- Michael A. Metzger
- Independent Director
- --
- Dr. Santhosh Palani, C.F.A.
- Independent Director
- --
- Thomas Civik
- Independent Director
- 360.48K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.